ArticleEuropean radiology2026
Development and validation of the SYSU-score for MRI-based transmural healing assessment in Crohn's disease: a dual-center study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Raising the Bar in Crohn's Disease: Is Transmural Healing Achievable?Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesStandardizing magnetic resonance enterography (MRE)-defined transmural healing (TH) remains challenging in Crohn's disease (CD) despite its prognostic superiority. We aimed to evaluate seven conventional MRE-defined TH criteria and develop a machine-learning-optimized model for improved TH assessment. MATERIALS AND
methodsIn this double-center study, 467 active CD patients with 1263 MRE scans were stratified into three cohorts. Cohort 1 (n = 341) enabled retrospectively dual-metric comparison (attainment rate/prognostic protection) of seven MRE-defined TH criteria. Leveraging their strengths, we developed five machine-learning models for TH assessment to identify the optimal one. Semi-external validation was performed in prospective Ustekinumab (n = 92) and Upadacitinib (n = 34) cohorts.
resultsAmong seven conventional TH criteria, magnetic resonance index of activity (MaRIA), C-score, and simplified MaRIA (sMaRIA) demonstrated higher attainment rates (23.75%/28.74%/41.64%) and lower disease progression rates (14.81%/18.37%/25.35%). Random forest (RF) model showed the most favorable overall performance across cohorts: Cohort 1 (AUC, 0.82 vs. 0.71-0.81), Ustekinumab (AUC, 0.83 vs. 0.73-0.81), and Upadacitinib (AUC, 0.80 vs. 0.58-0.80) cohorts. Dual-metric evaluation identified the RF model and C-score as clinically applicable tools. Notably, the RF model (namely SYSU-score) was more strongly associated with lower progression risk than C-score: in the Ustekinumab cohort, SYSU-score-defined TH showed lower disease progression risk (HR = 0.07, p < 0.001) than C-score (HR = 0.15, p < 0.001); Upadacitinib cohort validated SYSU-score as the only system significantly associated with lower progression risk (HR = 0.20, p < 0.05).
conclusionsWe established a validated machine-learning-derived TH criterion integrating the strengths of conventional MRE-defined systems. SYSU-score-defined TH status was associated with lower progression risk with robust prognostic discrimination, advancing standardized TH assessment for clinical implementation. KEY POINTS: Question Among available MRI-based transmural healing (TH) criteria for Crohn's disease (CD), which are the most clinically applicable, and can a new model improve standardized prognostic assessment? Findings MaRIA, C-score, and sMaRIA showed relatively favorable clinical applicability, and the machine-learning-derived SYSU-score demonstrated robust prognostic performance in internal and semi-external validation. Clinical relevance SYSU-score may support more standardized MRI-based assessment of TH and improve risk stratification for disease progression in patients with CD.
Indexed as
Identifiers
42319405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.